Janko Samardzic

University of Belgrade Serbia

Dr. Janko Samardzic is an Assistant Professor and researcher at the Medical Faculty, University of Belgrade. He holds PhD in Medical Pharmacology and has extensive experience and expertise in Basic and Applied Neuroscience. Dr. Samardzic completed his postdoctoral studies at the University KU Leuven in Belgium and postgraduate specialty courses at the Erasmus University Medical Center Rotterdam. Currently, he also holds the position of Visiting Fellow at the University Children\'s Hospital Basel, Switzerland. Dr. Samardzic is a member of European Colleague of Neuropsychopharmacology, Austrian Pharmacological Society, Swiss Society for Clinical Pharmacology and Toxicology and Serbian Pharmacological Society. He is the author of a large number of peer reviewed papers and the regular speaker at the international scientific conferences. Janko is looking forward to continue juggling between the Serbia and Switzerland.

1books edited

2chapters authored

Latest work with IntechOpen by Janko Samardzic

This book collates the contributions of a selected number of neuroscientists that are interested in the molecular, preclinical, and clinical aspects of neurotransmission research. The seven chapters in this book address the latest research/review data related to GABA/glutamate system's organization and function, the structure of receptors, subtypes and their ligands, as well as the translational approach and clinical implications. The book offers readers a rich collection of data regarding current and future applications of GABA and glutamate neurotransmission, including promising research strategies and potential clinical benefits.

Go to the book

GABA And Glutamate

Edited by Janko Samardzic

Chapters authored

Benzodiazepines and Anxiety Disorders: From Laboratory to Clinic

By Janko Samardzic and Dubravka Svob Strac

Benzodiazepines (BDZs), which are among the most widely prescribed drugs in current psychiatric practice, act as positive modulators of GABAergic neurotransmission. They are used to treat a wide range of disorders, from anxiety, affective disorders and insomnia to epilepsy, alcohol withdrawal and muscle spasms. However, the development of tolerance and dependence after long‐term BDZ treatment, as well as the abuse potential, limit their use. Although some other classes of drugs are currently considered as a better choice for long‐term treatment, BDZs to date still remain indispensable drugs. They are widely prescribed for anxiety disorders, with high levels of evidence existing for the short‐term BDZ use in panic disorder and generalized anxiety disorder, intermediate for social anxiety and poor in post‐traumatic stress disorder and obsessive‐compulsive disorder. Future studies are intending to develop the new selective drugs that act via BDZ receptors, but with novel, narrow profile of action. Furthermore, the research on alternative therapeutic approaches of psychiatric disorders has shifted the focus onto therapeutic potential of natural BDZ ligands.

Part of the book: New Developments in Anxiety Disorders

Introductory Chapter: GABA/Glutamate Balance: A Key for Normal Brain Functioning

By Janko Samardzic, Dragana Jadzic, Boris Hencic, Jasna Jancic and Dubravka Svob Strac

Part of the book: GABA And Glutamate

Janko Samardzic

Latest work with IntechOpen by Janko Samardzic

GABA And Glutamate

Chapters authored

Related collaborators

Rudolf Gregurek

Alessandro Grecucci

Costina Păsărelu

Anca Dobrean

Costina Păsărelu

Dubravka Svob Strac

Daniele Chiffi

Ferdinando Di Marzio

Remo Job

Jon Frederickson